Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency
Thrombosis and Haemostasis · 01.09.2026 · 126 (09) · 919-929
DOI: 10.1055/a-2715-2994 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.09.2026. Verfasst von Claudia Djambas Khayat und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hotel Dieu de France Hospital Beirut, Saint Joseph University, Lebanon. Hauptthemen laut MEDLINE: Fibrinogen, Afibrinogenemia, Hemostasis, Hemostatics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Congenital fibrinogen deficiencies are rare coagulopathies which are treated by fibrinogen concentrates. This trial investigated the pharmacokinetic/pharmacodynamic (PK/PD) parameters, and surrogate efficacy and safety of a new human fibrinogen concentrate (HFC), BT524, in patients with congenital afibrinogenemia or severe hypofibrinogenemia. This prospective, multi-national, open-label, single-arm PK/PD trial evaluated PK/PD parameters of HFC (part 1; phase I) and HFC as on-demand treatment or prophylaxis for bleeding events (part 2; phase III). In part 1, patients received a single-dose of HFC (70 mg/kg body weight [BW]). PK/PD parameters were calculated using a PK/PD model and non-compartmental analysis. Fibrinogen antigen (FiAg) levels were determined over 14 days by immunonephelometry and fibrinogen activity (FiAc) by Clauss assay. The efficacy variable was mean change in maximum clot firmness (MCF) analyzed by thromboelastometry. Safety parameters were evaluated for 49 days. A total of 27 patients (n = 15 adults, n = 12 children) were treated with HFC. For FiAg, mean (SD) PK parameters were: Cmax 1.81 (0.42) g/L, AUC0-∞ 173 (45.4) g*h/L, and t1/2 67.9 (15.3) h. For FiAc, they were Cmax 1.26 (0.4) g/L, AUC0-∞ 104 (33.5) g*h/L, and t1/2 60.3 (13.3) h. In adults, MCF significantly increased 1 h after HFC infusion (11.1 (5.1) mm; P < 0.0001; 95% CI: 9.33–14.47). In pediatrics, mean increase in range was 9.3 to 16.5 mm. Treatment-related adverse events were rare, with one mild increase in fibrin D-dimer. No thromboembolic events, hypersensitivity, or allergic reactions were observed. HFC effectively increased FiAg levels and FiAc, improved clot firmness, and showed a favorable safety and tolerability profile in adult and pediatric patients with congenital fibrinogen deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Hotel Dieu de France Hospital Beirut, Saint Joseph University, Lebanon.
- Pediatric Hospital CU, Egyptian Thalassemia Association, El Cairo, Egypt.
- Hospital Aziza Othmana, Tunis, Tunisia.
- Hospital Farhat Hached, Faculte de Medecine Ibn El Jazzar, Sousse University, Tunisia.
- Department of Haemostasis/Haemophilia Centre, Medical Clinic 2, University Hospital Frankfurt, Frankfurt, Germany.
- National Research Center, Pediatric Hematology Department, El Cairo, Egypt.
ORCID-Profile: Wolfgang Miesbach
Zitieren
APA
Djambas Khayat, C., El-Beshlawy, A., Meddeb, B., Khelif, A., Miesbach, W., Adolf, S., Boehm, H., Aigner, S., Abraha, S., Bohlaender, F., & Schuettrumpf, J. (2026). Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency. Thrombosis and Haemostasis, 126(09), 919-929. https://doi.org/10.1055/a-2715-2994
Vancouver
Djambas Khayat C, El-Beshlawy A, Meddeb B, Khelif A, Miesbach W, Adolf S, et al. Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency. Thrombosis and Haemostasis. 2026;126(09):919-929. doi:10.1055/a-2715-2994
BibTeX
@article{DjambasKhayat2026,
author = {Djambas Khayat, Claudia and El-Beshlawy, Amal and Meddeb, Balkis and Khelif, Abderrahim and Miesbach, Wolfgang and Adolf, Sonia and Boehm, Heike and Aigner, Silke and Abraha, Salomon and Bohlaender, Fabian and Schuettrumpf, Joerg},
title = {Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {09},
pages = {919--929},
doi = {10.1055/a-2715-2994}
}
EUVIMED